| Acasti Pharma is a biopharmaceutical company focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids (OM3) delivered both as free fatty acids and bound-to-phospholipid esters derived from krill oil. Co.'s primary product candidate is CaPre, an OM3 phospholipid therapeutic, which it is developing for the treatment of severe hypertriglyceridemia, a condition characterized by high or severe levels of triglycerides in the bloodstream. The ACST YTD return is shown above.
The YTD Return on the ACST YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ACST YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACST YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.